AD-REAL: A Prospective, Multinational, Observational Cohort Study of Clinical Effectiveness and Treatment Discontinuation of Oral Systemics for Moderate-to-Severe Atopic Dermatitis
Abstract
Introduction: Clinical data surrounding treatment patterns and reasons for discontinuation of oral systemics (OS) for the treatment of adult patients with moderate-severe atopic dermatitis (AD) remain limited. AD-REAL descriptively reports the discontinuation rates and treatment responses at week (W) 24 for patients with AD initiating new OS treatments. Methods: AD-REAL is a 12-month, multinational, observational cohort study of adult patients with moderate-to-severe AD commencing either conventional systemics (CS) or baricitinib. Other Janus kinase inhibitors (JAKis) were analyzed ad hoc. The primary objective reported the discontinuation rate of patients at W24 from baseline. Secondary objectives reported outcomes for Eczema Area and Severity index
Related
- Outcomes of patients with suspected or confirmed melioidosis: A prospective multinational, multicenter, observational study
- Multimodal protective and susceptibility clusters in paediatric atopic dermatitis: A machine learning-based, data-driven observational study
- Plasma Dimethylarginine Concentrations in Dogs With Large Cell Lymphoma or Hemangiosarcoma: A Prospective Observational Study
- Safety of lecanemab in real-world patients with Alzheimer’s disease: a prospective, observational case series supported by FAERS signal analysis
- Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study
BibTeX
@article{augustin2026adreal,
title = {{AD-REAL: A Prospective, Multinational, Observational Cohort Study of Clinical Effectiveness and Treatment Discontinuation of Oral Systemics for Moderate-to-Severe Atopic Dermatitis}},
author = {Matthias Augustin and Andreas Pinter and Silvia Sabatino and Louis P Sanden and Pablo Chicharro and Esther Serra-Baldrich and Mahreen Ameen and Anthony Bewley and Walid Fakhouri and Inmaculada de la Torre and Julien Seneschal},
journal = {Dermatology and Therapy},
year = {2026},
month = jul,
doi = {10.1007/s13555-026-01852-5},
url = {https://u-bordeaux.hal.science/hal-05743608v1},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - AD-REAL: A Prospective, Multinational, Observational Cohort Study of Clinical Effectiveness and Treatment Discontinuation of Oral Systemics for Moderate-to-Severe Atopic Dermatitis
AU - Matthias Augustin
AU - Andreas Pinter
AU - Silvia Sabatino
AU - Louis P Sanden
AU - Pablo Chicharro
AU - Esther Serra-Baldrich
AU - Mahreen Ameen
AU - Anthony Bewley
AU - Walid Fakhouri
AU - Inmaculada de la Torre
AU - Julien Seneschal
PY - 2026
DA - 2026/07/30
JO - Dermatology and Therapy
DO - 10.1007/s13555-026-01852-5
UR - https://u-bordeaux.hal.science/hal-05743608v1
AB - Introduction: Clinical data surrounding treatment patterns and reasons for discontinuation of oral systemics (OS) for the treatment of adult patients with moderate-severe atopic dermatitis (AD) remain limited. AD-REAL descriptively reports the discontinuation rates and treatment responses at week (W) 24 for patients with AD initiating new OS treatments. Methods: AD-REAL is a 12-month, multinational, observational cohort study of adult patients with moderate-to-severe AD commencing either conventional systemics (CS) or baricitinib. Other Janus kinase inhibitors (JAKis) were analyzed ad hoc. The primary objective reported the discontinuation rate of patients at W24 from baseline. Secondary objectives reported outcomes for Eczema Area and Severity index
SN - 2193-8210
SN - 2193-8210
ER -